炎症性肠病治疗药物辅料相关不良反应的研究进展

Research Progress on the Risk of Excipients-Related Adverse Reactions in Pharmaceutical Preparations for IBD Treatment

  • 摘要: 炎症性肠病(inflammatory bowel disease,IBD)患者需长期接受药物治疗,而临床可用药品种类繁多,其用药安全问题日益突出。药物辅料作为药物制剂中不可或缺的组成部分,可能诱发皮疹、过敏反应、胃肠道不适等多种不良反应,甚至导致严重机体损伤,然而其在临床实践中常被忽视。因此,识别和应对辅料相关不良反应对临床用药安全至关重要。为此,本文系统梳理了IBD治疗药物中的常见辅料、导致不良反应的相关机制以及管理策略,旨在提高临床医生对辅料相关问题的认识,提升识别与处理能力,保障患者用药安全。

     

    Abstract: Patients with inflammatory bowel disease (IBD) require long-term pharmacotherapy. Due to the wide variety of clinically available drugs, medication safety has become increasingly concerning. As an indispensable component of pharmaceutical formulations, drug excipients may induce various adverse reactions, including rash, allergic responses, and gastrointestinal discomfort, and may even lead to severe organic injury. However, they are often overlooked in clinical practice. Therefore, identifying and managing excipientrelated adverse reactions is crucial for ensuring medication safety. To address this issue, this article systematically reviews common excipients in IBD therapeutics, the underlying mechanisms of excipient-induced adverse reactions, and corresponding management strategies, aiming to enhance clinicians' awareness of excipient-related issues, improve their ability to recognize and manage such reactions, and ultimately ensure patient safety.

     

/

返回文章
返回